Gene therapy for prostate cancer

Postgraduate Medicine

Volumn 122, Issue 3, 2010, Pages 166-180

  Tangney, Mark ^a   Ahmad, Sarfraz ^a   Collins, Sara A ^a   O'Sullivan, Gerald C ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Gene therapy; Malignant; Prostate cancer; Tumor; Urology; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CYTOSINE DEAMINASE; DIPHTHERIA TOXIN; DNA VACCINE; DOCETAXEL; ENDOSTATIN; FLUCYTOSINE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPESVIRUS VECTOR; INTERLEUKIN 12; INTERLEUKIN 2; LENTIVIRUS VECTOR; ONCOLYTIC NEWCASTLE DISEASE PARAMYXOVIRUS; ONCOLYTIC PARVOVIRUS; ONCOLYTIC REOVIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; PARVOVIRUS VECTOR; PLASMID DNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAD; PROTEIN BAX; PROTEIN P53; RETROVIRUS VECTOR; SECONDARY LYMPHOID TISSUE CHEMOKINE; THYMIDINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLISTIC TRANSFORMATION; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RADIOTHERAPY; DNA IMMUNIZATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; ELECTROPORATION; ESCHERICHIA COLI; FLU LIKE SYNDROME; GAMMA IRRADIATION; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE TARGETING; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LASER; LIPOSOMAL GENE DELIVERY SYSTEM; LISTERIA; LOW DRUG DOSE; LUNG METASTASIS; MICROINJECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; PROSTATE CANCER; SALMONELLA; SUICIDE GENE THERAPY; TUMOR CELL DESTRUCTION; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; ANIMAL; GENE THERAPY; GENE VECTOR; IMMUNOTHERAPY; MALE; MOUSE; PROSTATE TUMOR;

ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MALE; MICE; PROSTATIC NEOPLASMS;

EID: 77953097036     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.05.2154     Document Type: Article

References (156)

1. Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8iiT cells. Cancer Immunol Immunother. 2007;56(6):885-895.
2. Jemal A, Tiwari RC, Murray T, et al; American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin. 2004;54(1):8-29.
3. Lassi K, Dawson NA. Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol. 2010;22(3):263-267.
4. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993;118(10):793-803.
5. Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology. 2000;55(3):323-327.
6. Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother. 2007;56(1):81-87.
7. Buhles A, Collins SA, van Pijkeren JP, et al. Anti-metastatic effects of viral and non-viral mediated Nk4 delivery to tumours. Genet Vaccines Ther. 2009;7:5.
8. Shi F, Rakhmilevich AL, Heise CP, et al. Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Mol Cancer Ther. 2002;1(11):949-957.
9. Walther W, Stein U, Fichtner I, et al. Intratumoral low-volume jet-injection for efficient nonviral gene transfer. Mol Biotechnol. 2002;21(2):105-115.
10. Kawabata K, Takakura Y, Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm Res. 1995;12(6):825-830.
11. Lechardeur D, Sohn KJ, Haardt M, et al. Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Ther. 1999;6(4):482-497.
12. Palffy R, Gardlik R, Hodosy J, et al. Bacteria in gene therapy: bactofection versus alternative gene therapy. Gene Ther. 2006;13(2):101-105.
13. Friedmann T. The Development of Human Gene Therapy. New York, NY: Cold Spring Harbor Laboratory Press; 1999.
14. Templeton N, Lasic D, eds. Gene therapy: therapeutic mechanisms and strategies. In: Gene Therapy: Therapeutic Mechanisms and Strategies. New York, NY: Marcel Dekker, Inc.; 2000.
15. Collins SA, Guinn BA, Harrison PT, Scallan MF, O'Sullivan GC, Tangney M. Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther. 2008;8(2):66-78.
16. Schenk E, Essand M, Bangma C. Clinical adenoviral gene therapy for prostate cancer [published online ahead of print December 10, 2009]. Hum Gene Ther.
17. de Vrij J, Willemsen RA, Lindholm L, Hoeben RC. Adenovirus-derived vectors for prostate cancer gene therapy [published online ahead of print March 25, 2010]. Hum Gene Ther.
18. Cusack JC Jr, Tanabe KK. Introduction to cancer gene therapy. Surg Oncol Clin N Am. 2002;11(3):497-519, v.
19. Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol. 2003;21(3):117-122.
20. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4(5):346-358.
21. Emtage PC, Wan Y, Hitt M, et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther. 1999;10(5):697-709.
22. Nasu Y, Bangma CH, Hull GW, et al. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther. 1999;6(3):338-349.
23. Yamamoto M, Curiel DT. Cancer gene therapy. Technol Cancer Res Treat. 2005;4(4):315-330.
24. Morrow JF, Cohen SN, Chang AC, Boyer HW, Goodman HM, Helling RB. Replication and transcription of eukaryotic DNA in Escherichia coli. Proc Natl Acad Sci U S A. 1974;71(5):1743-1747.
25. Walsh M, Tangney M, O'Neill MJ, et al. Evaluation of cellular uptake and gene transfer efficiency of pegylated poly-L-lysine compacted DNA: implications for cancer gene therapy. Mol Pharm. 2006;3(6):644-653.
26. Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genet Vaccines Ther. 2010;8(1):1.
27. Tangney M, Casey G, Larkin JO, et al. Non-viral in vivo immune gene therapy of cancer: combined strategies for treatment of systemic disease. Cancer Immunol Immunother. 2006;55(11):1443-1450.
28. Casey G, Cashman JP, Morrissey D, et al. Sonoporation mediated immunogene therapy of solid tumours. Ultrasound Med Biol. 2010;36(3):430-440.
29. Tangney M, Gahan CG. Listeria monocytogenes as a vector for anticancer therapies. Curr Gene Ther. 2010;10(1):46-55.
30. Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J Pathol. 2006;208(2):290-298.
31. Moreno M, Kramer MG, Yim L, Chabalgoity JA. Salmonella as live trojan horse for vaccine development and cancer gene therapy. Curr Gene Ther. 2010;10(1):56-76.
32. Buttaro C, Fruehauf JH. Engineered E. coli as vehicles for targeted therapeutics. Curr Gene Ther. 2010;10(1):27-33.
33. Tangney M, Gahan CG. Listeria monocytogenes as a vector for anticancer therapies. Curr Gene Ther. 2010;10(1):46-55.
34. Alton EW, Middleton PG, Caplen NJ, et al. Non-invasive liposomemediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat Genet. 1993;5(2):135-142.
35. Huber PE, Pfisterer P. In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound. Gene Ther. 2000;7(17):1516-1525.
36. Taniyama Y, Tachibana K, Hiraoka K, et al. Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther. 2002;9(6):372-380.
37. Duvshani-Eshet M, Benny O, Morgenstern A, Machluf M. Therapeutic ultrasound facilitates antiangiogenic gene delivery and inhibits prostate tumor growth. Mol Cancer Ther. 2007;6(8):2371-2382.
38. Clapé C, Fritz V, Henriquet C, et al. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One. 2009;4(10):e7542.
39. Mikata K, Uemura H, Ohuchi H, Ohta S, Nagashima Y, Kubota Y. Inhibition of growth of human prostate cancer xenograft by transfection of p53 gene: gene transfer by electroporation. Mol Cancer Ther. 2002;1(4):247-252.
40. Wu F, Wang ZB, Chen WZ, et al. Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma. Ann Surg Oncol. 2004;11(12):1061-1069.
41. Morrissey D, O'Sullivan GC, Tangney M. Tumour targeting with systemically administered bacteria. Curr Gene Ther. 2010;10(1):3-14.
42. Cronin M, Morrissey D, Rajendran S, et al. Orally administered bifidobacteria as a vehicle for delivery of agents to systemic tumours [published online ahead of print April 13, 2010]. Mol Ther.
43. Mengesha A, Wei JZ, Zhou SF, Wei MQ. Clostridial spores to treat solid tumours-potential for a new therapeutic modality. Curr Gene Ther. 2010;10(1)15-26.
44. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A. 2001;98(26):15155-15160.
45. van Pijkeren JP, Morrissey D, Monk IR, et al. A novel listeria monocytogenes-based DNA delivery system for cancer gene therapy. Hum Gene Ther. 2010;21(4):405-416.
46. Zhao M, Yang M, Li XM, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A. 2005;102(3):755-760.
47. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science. 1994;266(5189):1373-1376.
48. Han X, Kasahara N, Kan YW. Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci U S A. 1995;92(21):9747-9751.
49. Cosset FL, Morling FJ, Takeuchi Y, Weiss RA, Collins MK, Russell SJ. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol. 1995;69(10):6314-6322.
50. Marin M, Noël D, Valsesia-Wittman S, et al. Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J Virol. 1996;70(5):2957-2962.
51. Kircheis R, Schuller S, Brunner S, et al. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J Gene Med. 1999;1(2):111-120.
52. Tam P, Monck M, Lee D, et al. Stabilized plasmid-lipid particles for systemic gene therapy. Gene Ther. 2000;7(21):1867-1874.
53. Monck MA, Mori A, Lee D, et al. Stabilized plasmid-lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection. J Drug Target. 2000;7(6):439-452.
54. Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. Transferrin-liposomemediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther. 1999;10(18):2941-2952.
55. Lu Y. Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer. Adv Drug Deliv Rev. 2009;61(7-8):572-588.
56. Lee CH, Liu M, Sie KL, Lee MS. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer. Anticancer Res. 1996;16(4A):1805-1811.
57. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther. 1998;9(11):1617-1626.
58. Figueiredo ML, Kao C, Wu L. Advances in preclinical investigation of prostate cancer gene therapy. Mol Ther. 2007;15(6):1053-1064.
59. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A. 1995;92(8):3439-3443.
60. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 1997;57(16):3325-3330.
61. Haga K, Tomioka A, Liao CP, et al. PTEN knockout prostate cancer as a model for experimental immunotherapy. J Urol. 2009;181(1):354-362.
62. Shirakawa T, Fujisawa M, Gotoh A. Gene therapy in prostate cancer: past, present and future. Front Biosci. 2008;13:2115-2119.
63. MacRae EJ, Giannoudis A, Ryan R, et al. Gene therapy for prostate cancer: current strategies and new cell-based approaches. Prostate. 2006;66(5):470-494.
64. Eder IE, Haag P, Bartsch G, Klocker H. Gene therapy strategies in prostate cancer. Curr Gene Ther. 2005;5(1):1-10.
65. Freytag SO, Stricker H, Movsas B, Kim JH. Prostate cancer gene therapy clinical trials. Mol Ther. 2007;15(6):1042-1052.
66. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407(6805):770-776.
67. Lowe SL, Rubinchik S, Honda T, McDonnell TJ, Dong JY, Norris JS. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells. Gene Ther. 2001;8(18):1363-1371.
68. Zhang Y, Yu J, Unni E, et al. Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB. Hum Gene Ther. 2002;13(17):2051-2064.
69. Cowen D, Salem N, Ashoori F, et al. Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Clin Cancer Res. 2000;6(11):4402-4408.
70. Pisters LL, Pettaway CA, Troncoso P, et al. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res. 2004;10(8):2587-2593.
71. Zheng JY, Chen D, Chan J, Yu D, Ko E, Pang S. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A. Cancer Gene Ther. 2003;10(10):764-770.
72. Freeman SM. Suicide gene therapy. Adv Exp Med Biol. 2000;465:411-422.
73. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 1994;54(23):6228-6234.
74. Yoshimura I, Suzuki S, Tadakuma T, Hayakawa M. Suicide gene therapy on LNCaP human prostate cancer cells. Int J Urol. 2001;8(7):S5-S8.
75. Chen L, Pulsipher M, Chen D, et al. Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. J Clin Invest. 1996;98(11):2539-2548.
76. Eaton JD, Perry MJ, Todryk SM, et al. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques. Gene Ther. 2001;8(7):557-567.
77. Ikegami S, Tadakuma T, Ono T, et al. Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/ enhancer in a castrated mouse model of prostate cancer. Cancer Sci. 2004;95(4):367-370.
78. Ikegami S, Tadakuma T, Suzuki S, Yoshimura I, Asano T, Hayakawa M. Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition. Jpn J Cancer Res. 2002;93(10):1154-1163.
79. Zhang Z, Yin L, Zhang Y, Zhao F. In situ transduction of cytosine deaminase gene followed by systemic use of 5-fluorocytosine inhibits tumor growth and metastasis in orthotopic prostate cancer mouse models. Chin Med J (Engl). 2002;115(2):227-231.
80. Martiniello-Wilks R, Wang XY, Voeks DJ, et al. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med. 2004;6(12):1343-1357.
81. Nasu Y, Saika T, Ebara S, et al. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther. 2007;15(4):834-840.
82. Both GW. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Curr Opin Mol Ther. 2009;11(4):421-432.
83. Alain T, Hirasawa K, Pon KJ, et al. Reovirus therapy of lymphoid malignancies. Blood. 2002;100(12):4146-4153.
84. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW. Oncolytic reovirus against ovarian and colon cancer. Cancer Res. 2002;62(6):1696-1701.
85. Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther. 2002;13(5):641-652.
86. Mullen JT, Tanabe KK. Viral oncolysis. Oncologist. 2002;7(2):106-119.
87. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett. 2001;172(1):27-36.
88. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6(7):821-825.
89. Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anticancer agents. Cancer Cell. 2003;4(4):263-275.
90. Haag A, Menten P, Van Damme J, Dinsart C, Rommelaere J, Cornelis JJ. Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Hum Gene Ther. 2000;11(4):597-609.
91. Herrero YC, Cornelis JJ, Herold-Mende C, Rommelaere J, Schlehofer JR, Geletneky K. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer. 2004;109(1):76-84.
92. Moehler M, Blechacz B, Weiskopf N, et al. Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Ther. 2001;8(3):158-167.
93. Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. Reovirus: viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol). 2008;20(7):548-554.
94. Norman KL, Lee PW. Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today. 2005;10(12):847-855.
95. Thirukkumaran CM, Nodwell MJ, Hirasawa K, et al. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res. 2010;70(6):2435-2444.
96. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med. 2000;6(10):1134-1139.
97. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61(20):7464-7472.
98. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigenpositive prostate cancer cells. Cancer Res. 1997;57(13):2559-2563.
99. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 1999;59(17):4200-4203.
100. Small EJ, Carducci MA, Burke JM, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006;14(1):107-117.
101. Thirukkumaran CM, Nodwell MJ, Hirasawa K, et al. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res. 2010;70(6):2435-2444.
102. Liu C, Zhang Y, Liu MM, et al. Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. Int J Radiat Biol. 2010;86(3):220-229.
103. Cozzi PJ, Burke PB, Bhargav A, et al. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate. 2002;53(2):95-100.
104. Oyama M, Ohigashi T, Hoshi M, Murai M, Uyemura K, Yazaki T. Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207. Jpn J Cancer Res. 2000;91(12):1339-1344.
105. Murphy J, O'Sullivan GC, Lee G, et al. The inflammatory response within Dukes' B colorectal cancers: implications for progression of micrometastases and patient survival. Am J Gastroenterol. 2000;95(12):3607-3614.
106. Borrello I, Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev. 2002;13(2):185-193.
107. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996;184(3):1075-1082.
108. Shevach EM. CD411CD25CCsuppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2(6):389-400.
109. Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol. 2007;19(2):203-208.
110. Weiner LM. Cancer immunotherapy-the endgame begins. N Engl J Med. 2008;358(25):2664-2665.
111. Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999;59(20):5160-5168.
112. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000;6(5):1632-1638.
113. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormonerefractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18(23):3894-3903.
114. Pavlenko M, Roos AK, Lundqvist A, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer. 2004;91(4):688-694.
115. Mincheff M, Tchakarov S, Zoubak S, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol. 2000;38(2):208-217.
116. Yousefieh N, Hahto SM, Stephens AL, Ciavarra RP. Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Microenviron. 2009;2(1):59-67.
117. Trudel S, Trachtenberg J, Toi A, et al. A phase I trial of adenovectormediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther. 2003;10(10):755-763.
118. Belldegrun A, Tso CL, Zisman A, et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther. 2001;12(8):883-892.
119. Ward JE, McNeel DG. GVAX: an allogeneic, whole-cell, GM-CSFsecreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther. 2007;7(12):1893-1902.
120. Antonarakis ES, Drake CG. Current status of immunological therapies for prostate cancer. Curr Opin Urol. 2010;20(3):241-246.
121. Doehn C, Böhmer T, Jocham D. Technology evaluation: Onyvax-P, Onyvax. Curr Opin Mol Ther. 2005;7(5):511-519.
122. Copier J, Dalgleish A. Overview of tumor cell-based vaccines. Int Rev Immunol. 2006;25(5-6):297-319.
123. Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther. 2009;17(6):1101-1108.
124. Low L, Mander A, McCann K, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther. 2009;20(11):1269-1278.
125. MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis. 1998;178(1):92-100.
126. Marshall DJ, San Mateo LR, Rudnick KA, et al. Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine. Cancer Immunol Immunother. 2005;54(11):1082-1094.
127. Stevenson FK, Ottensmeier CH, Rice J. DNA vaccines against cancer come of age. Curr Opin Immunol. 2010;22(2):264-270.
128. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008;8(2):108-120.
129. Malecki M, Kolsut P, Proczka R. Angiogenic and antiangiogenic gene therapy. Gene Ther. 2005;12(suppl 1):S159-S169.
130. Holleb AI, Folkman J. Tumor angiogenesis. CA Cancer J Clin. 1972;22(4):226-229.
131. Folkman J. The vascularization of tumors. Sci Am. 1976;234(5):58-64,70-73.
132. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676.
133. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer. 2001;1(2):130-141.
134. Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer. 2000;89(6):1181-1194.
135. Kim WJ, Chang CW, Lee M, Kim SW. Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. J Control Release. 2007;118(3):357-363.
136. Zhao P, Luo R, Wu J, et al. E10A, an adenovirus carrying human endostatin gene, in combination with docetaxel treatment inhibits prostate cancer growth and metastases [published online ahead of print October 13, 2008]. J Cell Mol Med.
137. Jin RJ, Kwak C, Lee SG, et al. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther. 2000;7(12):1537-1542.
138. Song W, Dong Z, Jin T, Mantellini MG, Núnez G, Nör JE. Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells. Cancer Gene Ther. 2008;15(10):667-675.
139. Isayeva T, Moore LD, Chanda D, Chen D, Ponnazhagan S. Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status. Prostate. 2009;69(10):1055-1066.
140. Wen Y, Giri D, Yan DH, et al. Prostate-specific antitumor activity by probasin promoter-directed p202 expression. Mol Carcinog. 2003;37(3):130-137.
141. Freytag SO, Paielli D, Wing M, et al. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys. 2002;54(3):873-885.
142. Saika T, Satoh T, Kusaka N, et al. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model. Cancer Gene Ther. 2004;11(5):317-324.
143. Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genet Vaccines Ther. 8(1):1.
144. Medin JA, Liang SB, Hou JW, Kelley LS, Peace DJ, Fowler DH. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther. 2005;12(6):540-551.
145. Herman JR, Adler HL, Aguilar-Cordova E, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther. 1999;10(7):1239-1249.
146. Miles BJ, Shalev M, Aguilar-Cordova E, et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001;12(16):1955-1967.
147. Kubo H, Gardner TA, Wada Y, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormonerefractory prostate cancer. Hum Gene Ther. 2003;14(3):227-241.
148. Teh BS, Ayala G, Aguilar L, et al. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004;58(5):1520-1529.
149. Freytag SO, Stricker H, Peabody J, et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther. 2007;15(3):636-642.
150. Freytag SO, Khil M, Stricker H, et al. Phase I study of replicationcompetent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002;62(17):4968-4976.
151. Sanda MG, Ayyagari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol. 1994;151(3):622-628.
152. Sanda MG, Smith DC, Charles LG, et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology. 1999;53(2):260-266.
153. Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2004;22(11):2122-2132.
154. Pantuck AJ, van Ophoven A, Gitlitz BJ, et al. Phase I trial of antigenspecific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother. 2004;27(3):240-253.
155. Cell Genesys reports long-term survival data in Phase II trial of GVAX. Expert Rev Anticancer Ther. 2002;2(3):245-246.
156. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate. 2004;60(3):197-204.